Canada markets open in 8 hours 40 minutes

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.61-0.12 (-0.51%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close23.73
Open23.57
Bid0.00 x 1400
Ask0.00 x 1200
Day's Range22.76 - 23.99
52 Week Range9.12 - 43.32
Volume326,643
Avg. Volume698,110
Market Cap1.909B
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-2.68
Earnings DateNov. 08, 2021 - Nov. 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.00
  • Simply Wall St.

    Those who invested in Alector (NASDAQ:ALEC) a year ago are up 134%

    Alector, Inc. ( NASDAQ:ALEC ) shareholders might understandably be very concerned that the share price has dropped 33...

  • GlobeNewswire

    Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company’s Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology. “Betsy is a highly-regarded leader with unmatched clinical

  • GlobeNewswire

    Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS)

    Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the first participant has been dosed in a Phase 2 clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AL001 in people with amyotrophic lateral sclerosis (ALS) who carry a C9orf72 mut